Business · 20/10/2005
FDA Releases Guidance on Delayed Ventricular Repolarization for Human Pharmaceuticals
The FDA has made available a guidance document outlining a nonclinical testing strategy to assess the potential of pharmaceuticals to delay ventricular repolarization, a condition that can increase the risk of arrhythmias.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →